4830 W. KENNEDY BLVD., TAMPA, FL
Inhibitor Therapeutics, Inc. Enters $3M Financing Agreement with Investor
Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
Inhibitor Therapeutics Enters $3M Securities Purchase Agreement
Inhibitor Therapeutics Enters Performance-Based Agreement with Frameshift Man...
Material Contracts, Other Events
Changes in Board, Management or Compensation, Amendments to Articles of Incorporation or Bylaws
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement
Confidential Treatment Order